Citation: Badalucco S, Di Buduo CA, Campanelli R, Pallotta I, Catarsi P, Rosti V, Kaplan DL, Barosi G, Massa M, and Balduini A. Involvement of TGF 1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis. Haematologica. 2013; 98:xxx doi:10.3324/haematol.2012 Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haematologica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature. Growth Factor beta 1 this mechanism seems to be preserved in primary myelofibrosis.
to be active in megakaryocytes extending proplatelets, indicating a type of autocrine stimulation on megakaryocyte development. Further, inactivation of Transforming Growth Factor beta 1 signaling, by the receptor inhibitors SB431542 and Stemolecule ALK5 inhibitor, determined a significant decrease of proplatelet formation. Recent studies pointed out a crucial role of Transforming Growth Factor beta 1 in the pathogenesis of primary myelofibrosis. We demonstrated that primary myelofibrosis derived megakaryocytes expressed increased levels of bioactive Transforming Growth Factor beta 1; however higher levels of released Transforming Growth Factor beta 1 did not lead to enhanced activation of downstream pathways. Overall these data propose Transforming Growth Factor beta 1 as a new element in the autocrine regulation of proplatelet formation in vitro; despite the increase of Transforming Growth Factor beta 1 this mechanism seems to be preserved in primary myelofibrosis. 
INTRODUCTION
Megakaryocyte maturation and platelet generation in bone marrow (BM) result from megakaryocyte migration from the osteoblastic to the vascular niche, where megakaryocytes extend proplatelets and release newly generated platelets into the bloodstream. 1 Megakaryocytes are "filled" with different fibrogenic factors, among which transforming growth factor beta1 (TGFβ1) mostly contributes to BM fibrosis associated with BM disorders, like hairy cell leukemia and myelofibrosis. 2, 3 Besides its fibrogenic activity, TGFβ is a pleiotropic regulator of all stages of hematopoiesis which activity depends on the differentiation stage of the target cell, the local environment and the concentration. 4, 5 However, the role of TGFβ1 on megakaryocyte proliferation, differentiation and proplatelet formation is poorly investigated. Kuroda et al. reported that TGFβ1 is involved in negative feed-back regulation of megakaryopoiesis in healthy volunteers and that megakaryocyte colony-forming units of patients with the myeloproliferative neoplasm essential thrombocythemia are less sensitive to TGFβ1 than normal subjects. 6 Moreover, Sakamaki et al. showed that
TGFβ1 determines an arrest of megakaryocyte colony forming unit maturation by enhancing the thrombopoietin-dependent expression of TGFβ1 receptors on megakaryoblasts.
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According to the evidence that hematopoietic precursors secrete several regulatory molecules that control various stages of normal human megakaryopoiesis in an autocrine and/or paracrine manner, [8] [9] [10] in this study we extended the search of autocrine growth factors for megakaryopoiesis to TGFβ1. We analyzed TGFβ1 influence on late stages of megakaryocyte maturation in cells from healthy subjects and we extended the study to patients with primary myelofibrosis (PMF), a chronic myeloproliferative neoplasm characterized by variable degrees of BM fibrosis associated with hyperplasia and atypia of megakaryocytes. 
RESULTS AND DISCUSSION
TGFβ1 mRNA was detected, by qRT-PCR, at a very early stage of megakaryocyte differentiation (day 7 of culture) and increased during megakaryocyte maturation with a peak at day 10 of culture ( Figure 1A ). Gene expression was paralleled by the release of the total and bioactive TGFβ1 proteins in the culture medium ( Figure 1B and 1C Figure 1F ) suggesting a possible role of these proteins in regulating platelet production. To address this hypothesis, megakaryocytes were preincubated, at day 13 of differentiation, with 10 µ M of TGFβ1 receptor kinase inhibitor, SB431542, a small synthetic molecule that interrupts the activation of signaling pathways downstream the TβRI, or 10 µM of Akt inhibitor VIII, AKTI-1/2.
Moreover, in order to confirm the effects of the TGFβ1 receptor inhibition, megakaryocytes were also treated with a specific TβRI inhibitor, Stemolecule ALK5
inhibitor (10 µM). As shown in Figure 1G , inhibition of all signaling resulted in a Figure 1A) . Interestingly, incubation with Stemolecule ALK5
inhibitor (10 µM) starting from day 10 of differentiation totally inhibited proplatelet formation (data not shown). Importantly, the decreased capacity of extending proplatelets by human megakaryocytes (Supplemental Figure 1B The positive effect of TGFβ1 on proplatelet formation by human megakaryocytes was confirmed by adding to the culture media 1 ng/ml TGFβ1. 16 As shown in Figure 1L , 3 Thus, the authors claimed that, due to their increased ability to produce TGFβ1, megakaryocytes may promote the generation of the bone marrow fibrosis in these patients, through a TGFβ1-mediated mechanism. Nevertheless, how increased levels of TGFβ1 impact megakaryopoiesis in PMF has never been explored. As shown in Figure 2A megakaryocytes, derived in vitro from peripheral blood CD34 + cells of PMF patients, presented decreased capacity of extending proplatelets, compared to megakaryocytes obtained from healthy controls circulating CD34 + cells.
On this basis, we investigated whether the impairment in proplatelet formation by PMF-derived megakaryocytes could be related to altered TGFβ1 signaling. Thus, total and bioactive levels of TGFβ1 were measured in the supernatant of megakaryocyte cultures from PMF progenitor cells and compared to controls. As shown in Figure   2B and 2C, increased levels of both total and bioactive TGFβ1 were observed in culture supernatants of PMF-derived megakaryocytes when compared to controls, during the entire process of megakaryocyte maturation. Importantly, no differences in TGFβ1 supernatant activity between patients with or without the JA K2 V617F mutation was observed (data not shown). As above reported, the high cell viability, demonstrated that increased TGFβ1 in the culture medium was consequent to active release from maturing megakaryocytes, rather than to damaged megakaryocyte in culture (data not shown). Thus, in order to investigate whether exposure to increased levels of TGFβ1 could enhance activation of TβR downstream signaling, we focused on mature megakaryocytes. First, we demonstrated similar expression of TβRI and TβRII in mature PMF derived megakaryocytes when compared to controls ( Figure   2D ). Second, we showed no differences in TβR downstream signaling between PMF and control derived megakaryocytes as demonstrated by similar levels of SMAD2/3 Figure 2F) . Unfortunately, because of the low percentage of proplatelet formation by PMF-derived megakaryocytes, the inhibitory effect of SB431542 was not significantly detectable (data not shown).
Overall, this is the first demonstration that TGFβ1, released by megakaryocytes, regulates proplatelet formation. Autocrine components, together with environmental factors, seem to play an important role in the regulation of platelet production. We recently demonstrated that ADP, released by megakaryocytes, regulates proplatelet formation by interacting with P2Y 13 . 10 The results we obtained in PMF provided confirmation that megakaryocytes produce excess amount of TGFβ1. 3 However, increased levels of released bioactive TGFβ1 by PMF-derived megakaryocytes did not enhance TGFβ1 receptor downstream signaling in the latest stages of megakaryocyte differentiation. Based on this evidence, the aberrant megakaryopoiesis that occurs in the fibrotic bone marrow of these patients could be due to an excess of TGFβ1 that affects the first stages of cell differentiation rather than proplatelet formation. In conclusion, our results propose a new role for TGFβ1 in the regulation of platelet production and open new perspectives on the mechanisms that trigger proplatelet formation by mature megakaryocytes.
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No author of this paper has a conflict of interest. Differentiation of megakaryocytes from human cord blood and peripheral blood CD34 + cells from human cord blood and peripheral blood were separated as previously described 1 and cultured for 13 days in Stem Span medium supplemented with 10 ng/mL TPO, IL-6, IL-11 at 37°C in a 5% CO 2 fully humidified atmosphere.
Medium was changed at day 3, 7 and 10 of culture. Cells at day 13 of culture were harvested, plated onto coverslips coated with fibrinogen 100 µg/ml in 24-wells plates were the folowing: 95° C for 30 sec followed by 40 cycles of 95°C for 5 sec and 60°C for 5 sec. Melting curves were generated after amplification in the range 65-95°C with increments of 0.5°C every 5 sec. The PCR data were collected using the CFX96 Real-Time System (Bio-Rad). Each sample was tested in duplicate.
Western blot analysis
In vitro differentiated megakaryocytes at day 7, day 10 and day 13 of differentiation or cord blood and peripheral blood derived megakaryocytes at day 13 of differentiation, pre-incubated or not with TGFβ receptor inhibitors, SB431542 or Stemolecule ALK5 inhibitor, as described above, were lysed with Hepes-glycerol lysis buffer (50 mM Hepes, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5% MgCl 2 , 1 mM EGTA) containing 1 mM phenylmethylsulphonylflouride (PMSF), 1 µg/ml leupeptin, 1µg/ml aprotinin, 1 mM Na 3 VO 4 , 1 mM NaF, on ice for 30 minutes.
Samples were clarified at 15700xg at 4°C for 15 minutes. Protein content was determined using the BCA assay. Proteins were separated using the SDSpolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane.
Membranes were blocked with 5% BSA containing 0.01% Tween-20 at room temperature for 1 hour and then incubated overnight at 4°C with primary antibodies against human TβRI, TβRII, pSMAD2/3, SMAD2/3, pAkt, Akt, PTEN or β-actin, diluted 1:1000 in 0.5% BSA containing 0.01% Tween-20. Immunoreactive bands were detected by horseradish peroxidase (HRP)-labeled secondary antibodies using enhanced chemiluminescence reagents.
Statistics
Values were expressed as mean ± SD (standard deviation). Student's t-test was performed for paired observations. A value of p<0.05 was considered statistically significant. Statistical analysis was carried out using SigmaStat 3.0 software.
ANOVA, followed by the post-hoc Bonferroni t-test was performed for grouped observations. A value of p<0.05 was considered statistically significant. All experiments were independently replicated at least 3 times, unless differently specified.
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